{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T05:42:47Z","timestamp":1760593367068,"version":"build-2065373602"},"reference-count":94,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.hoc.2023.12.004","type":"journal-article","created":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T08:23:52Z","timestamp":1703751832000},"page":"383-406","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Chimeric Antigen Receptor T Cells in the Treatment of Multiple Myeloma"],"prefix":"10.1016","volume":"38","author":[{"given":"Zainul S.","family":"Hasanali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Razzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra P.","family":"Susanibar-Adaniya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfred L.","family":"Garfall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward A.","family":"Stadtmauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam D.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2023.12.004_bib1","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.hoc.2023.12.004_bib2","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T\u00a0cells and increased antileukemic efficacy in\u00a0vivo","volume":"17","author":"Milone","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.hoc.2023.12.004_bib3","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1172\/JCI46110","article-title":"CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T\u00a0cells in lymphoma patients","volume":"121","author":"Savoldo","year":"2011","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.hoc.2023.12.004_bib4","doi-asserted-by":"crossref","first-page":"132ra53","DOI":"10.1126\/scitranslmed.3003761","article-title":"Decade-long safety and function of retroviral-modified chimeric antigen receptor T\u00a0cells","volume":"4","author":"Scholler","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.hoc.2023.12.004_bib5","doi-asserted-by":"crossref","first-page":"17372","DOI":"10.1073\/pnas.0608138103","article-title":"Gene transfer in humans using a conditionally replicating lentiviral vector","volume":"103","author":"Levine","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.hoc.2023.12.004_bib6","doi-asserted-by":"crossref","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T\u00a0cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.hoc.2023.12.004_bib7","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T\u00a0cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.hoc.2023.12.004_bib8","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2023.12.004_bib9","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2023.12.004_bib10","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1056\/NEJMoa1504542","article-title":"Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma","volume":"373","author":"Garfall","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2023.12.004_bib11","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1158\/0008-5472.CAN-07-3096","article-title":"Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance","volume":"68","author":"Matsui","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.hoc.2023.12.004_bib12","doi-asserted-by":"crossref","first-page":"e120505","DOI":"10.1172\/jci.insight.120505","article-title":"Anti-CD19 CAR T\u00a0cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma","volume":"3","author":"Garfall","year":"2018","journal-title":"JCI insight"},{"key":"10.1016\/j.hoc.2023.12.004_bib13","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jocit.2014.11.001","article-title":"CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T\u00a0cells for multiple myeloma","volume":"2","author":"Guo","year":"2016","journal-title":"J\u00a0Cell Immunother"},{"key":"10.1016\/j.hoc.2023.12.004_bib14","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1172\/JCI86000","article-title":"Clinical responses with T lymphocytes targeting malignancy-associated \u03ba light chains","volume":"126","author":"Ramos","year":"2016","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.hoc.2023.12.004_bib15","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.leukres.2018.07.015","article-title":"Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in Myeloma","volume":"71","author":"Salem","year":"2018","journal-title":"Leuk Res"},{"key":"10.1016\/j.hoc.2023.12.004_bib16","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2023.12.004_bib17","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T\u00a0Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2023.12.004_bib18","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B\u00a0cell maturation antigen-specific CAR T\u00a0cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.hoc.2023.12.004_bib19","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2023.12.004_bib20","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","article-title":"A\u00a0phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T\u00a0cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","volume":"11","author":"Zhao","year":"2018","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.hoc.2023.12.004_bib21","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2023.12.004_bib22","doi-asserted-by":"crossref","first-page":"8036","DOI":"10.1200\/JCO.2021.39.15_suppl.8036","article-title":"Characteristics of neurotoxicity associated with idecabtagene vicleucel (ide-cel, bb2121) in patients with relapsed and refractory multiple myeloma (RRMM) in the pivotal phase II KarMMa study","volume":"39","author":"Manier","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2023.12.004_bib23","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2217\/cer-2022-0045","article-title":"Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma","volume":"11","author":"Shah","year":"2022","journal-title":"J\u00a0Comp Eff Res"},{"key":"10.1016\/j.hoc.2023.12.004_bib24","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1080\/10428194.2021.1913143","article-title":"Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor\u00a0+ dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma","volume":"62","author":"Rodriguez-Otero","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hoc.2023.12.004_bib25","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-021-00507-2","article-title":"KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma","volume":"11","author":"Jagannath","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.hoc.2023.12.004_bib26","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1186\/s12885-023-10824-3","article-title":"Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed\/refractory multiple myeloma patients","volume":"23","author":"Sanoyan","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.hoc.2023.12.004_bib27","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene Vicleucel for Relapsed\/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2023.12.004_bib28","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1182\/blood-2022-164884","article-title":"Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM) Who Have Received a Prior BCMA-Targeted Therapy: Real World, Multi-Institutional Experience","volume":"140","author":"Ferreri","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.004_bib29","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2023.12.004_bib30","doi-asserted-by":"crossref","first-page":"8010","DOI":"10.1200\/JCO.2023.41.16_suppl.8010","article-title":"Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment of LCAR-B38M CAR-T: At least 5-year follow-up in LEGEND-2","volume":"41","author":"Mi","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2023.12.004_bib31","doi-asserted-by":"crossref","first-page":"e897","DOI":"10.1016\/S2352-3026(22)00284-8","article-title":"Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study","volume":"9","author":"Martin","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.hoc.2023.12.004_bib32","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.hoc.2023.12.004_bib33","doi-asserted-by":"crossref","first-page":"8009","DOI":"10.1200\/JCO.2023.41.16_suppl.8009","article-title":"CARTITUDE-1 final results: Phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma","volume":"41","author":"Lin","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2023.12.004_bib34","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1080\/03007995.2021.1953456","article-title":"Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma","volume":"37","author":"Martin","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.hoc.2023.12.004_bib35","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40261-021-01100-y","article-title":"Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician\u2019s Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma","volume":"42","author":"Weisel","year":"2022","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.hoc.2023.12.004_bib36","doi-asserted-by":"crossref","first-page":"8012","DOI":"10.1200\/JCO.2023.41.16_suppl.8012","article-title":"Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (Cilta-cel) for relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Hansen","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2023.12.004_bib37","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.004_bib38","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma","author":"San-Miguel","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2023.12.004_bib39","doi-asserted-by":"crossref","first-page":"LBA106","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA106","article-title":"First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma","volume":"41","author":"Dhakal","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2023.12.004_bib40","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1158\/2643-3230.BCD-22-0074","article-title":"Anti-BCMA\/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy","volume":"4","author":"Garfall","year":"2023","journal-title":"Blood cancer Discov"},{"key":"10.1016\/j.hoc.2023.12.004_bib41","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.1182\/blood-2022-168610","article-title":"Phase \u2161 Study of Fully Human BCMA-Targeting CAR-T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed\/Refractory Multiple Myeloma","volume":"140","author":"Chen","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.004_bib42","doi-asserted-by":"crossref","first-page":"8025","DOI":"10.1200\/JCO.2023.41.16_suppl.8025","article-title":"CT103A, a novel fully human BCMA-targeting CAR-T cells, in patients with relapsed\/refractory multiple myeloma: Updated results of phase 1b\/2 study (FUMANBA-1)","volume":"41","author":"Li","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2023.12.004_bib43","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1182\/bloodadvances.2022007210","article-title":"Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma","volume":"7","author":"Frigault","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.hoc.2023.12.004_bib44","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1182\/blood-2021-146518","article-title":"Updated Clinical and Correlative Results from the Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma","volume":"138","author":"Raje","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.004_bib45","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood-2020-142695","article-title":"Phase 1\/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed\/Refractory (r\/r) Multiple Myeloma (MM) (PRIME) with Novel Therapeutic Strategies","volume":"136","author":"Costello","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.004_bib46","doi-asserted-by":"crossref","first-page":"8504","DOI":"10.1200\/JCO.2020.38.15_suppl.8504","article-title":"Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T\u00a0cell therapy for patients (pts) with relapsed\/refractory multiple myeloma (RRMM): update of the phase 1\/2 EVOLVE study (NCT03430011)","volume":"38","author":"Mailankody","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2023.12.004_bib47","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1182\/blood-2022-160038","article-title":"Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633\/BMS-986354 in Patients (pts) with Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"140","author":"Costa","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.004_bib48","doi-asserted-by":"crossref","first-page":"8004","DOI":"10.1200\/JCO.2023.41.16_suppl.8004","article-title":"Updated phase I study results of PHE885, a T-Charge manufactured BCMA-directed CAR-T cell therapy, for patients (pts) with r\/r multiple myeloma (RRMM)","volume":"41","author":"Sperling","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2023.12.004_bib49","doi-asserted-by":"crossref","first-page":"8005","DOI":"10.1200\/JCO.2023.41.16_suppl.8005","article-title":"Updated results of a phase I, open-label study of BCMA\/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Du","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2023.12.004_bib50","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41591-022-02182-7","article-title":"Allogeneic BCMA-targeting CAR T\u00a0cells in relapsed\/refractory multiple myeloma: phase 1\u00a0UNIVERSAL trial interim results","volume":"29","author":"Mailankody","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.hoc.2023.12.004_bib51","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine release syndrome with chimeric antigen receptor T\u00a0cell therapy","volume":"25","author":"Frey","year":"2019","journal-title":"J\u00a0Am Soc Blood Marrow Transplant"},{"key":"10.1016\/j.hoc.2023.12.004_bib52","doi-asserted-by":"crossref","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.hoc.2023.12.004_bib53","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed\/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up","volume":"41","author":"Martin","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2023.12.004_bib54","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.hoc.2023.12.004_bib55","first-page":"2023020571","article-title":"Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T-cells","author":"Karschnia","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.004_bib56","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","article-title":"Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy","volume":"27","author":"Van Oekelen","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.hoc.2023.12.004_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2023.05.012","article-title":"Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy","author":"Davis","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.hoc.2023.12.004_bib58","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1182\/bloodadvances.2020004079","article-title":"Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy","volume":"6","author":"Kambhampati","year":"2022","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.hoc.2023.12.004_bib59","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/bjh.18909","article-title":"Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma","volume":"203","author":"Mohan","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2023.12.004_bib60","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1084\/jem.178.3.1023","article-title":"The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell","volume":"178","author":"Billadeau","year":"1993","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.hoc.2023.12.004_bib61","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1200\/JCO.21.01676","article-title":"Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma","volume":"40","author":"Wang","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2023.12.004_bib62","doi-asserted-by":"crossref","first-page":"8005","DOI":"10.1200\/JCO.2022.40.16_suppl.8005","article-title":"Updated results of a multicenter first-in-human study of BCMA\/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"40","author":"Du","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2023.12.004_bib63","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-Cell\u2013Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2023.12.004_bib64","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-Targeted CAR T Cells for Myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2023.12.004_bib65","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/S2352-3026(22)00372-6","article-title":"GPRC5D CAR T\u00a0cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial","volume":"10","author":"Zhang","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.hoc.2023.12.004_bib66","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1200\/JCO.22.01824","article-title":"Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase \u2161 Trial","volume":"41","author":"Xia","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2023.12.004_bib67","doi-asserted-by":"crossref","unstructured":"Bal, S. et\u00a0al. BMS-986393 (CC-95266), a G protein\u2013coupled receptor class C group5 member D (GPRC5D)\u2013targeted CAR T-cell therapy for relapsed\/refractory multiple myeloma (RRMM): results from a phase 1 study. EHA Libr. (2023).","DOI":"10.1097\/01.HS9.0000967684.98632.87"},{"key":"10.1016\/j.hoc.2023.12.004_bib68","doi-asserted-by":"crossref","unstructured":"Bahlis, N. et\u00a0al. Tumor Intrinsic Mechanisms of Antigen Escape to Anti-BCMA and Anti-GPRC5D Targeted Immunotherapies in Multiple Myeloma. (2023) doi:10.21203\/rs.3.rs-2657360\/v1.","DOI":"10.21203\/rs.3.rs-2657360\/v1"},{"key":"10.1016\/j.hoc.2023.12.004_bib69","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2023.12.004_bib70","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1038\/s41375-022-01559-4","article-title":"CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells","volume":"36","author":"O\u2019Neal","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2023.12.004_bib71","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1158\/1078-0432.CCR-17-0344","article-title":"Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma","volume":"24","author":"Wang","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2023.12.004_bib72","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1182\/blood-2022-170686","article-title":"Bispecific CS1-BCMA CAR-T Cells Are Clinically Active in Relapsed or Refractory Multiple Myeloma: An Updated Clinical Study","volume":"140","author":"Li","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.004_bib73","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1016\/S2352-3026(22)00378-7","article-title":"CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial","volume":"10","author":"Sallman","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.hoc.2023.12.004_bib74","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2023.12.004_bib75","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/j.ymthe.2017.04.024","article-title":"A\u00a0Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization","volume":"25","author":"Drent","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.hoc.2023.12.004_bib76","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.18632\/oncotarget.26792","article-title":"Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma","volume":"10","author":"Sun","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.hoc.2023.12.004_bib77","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.1038\/s41467-023-39395-4","article-title":"Chimeric antigen receptor T\u00a0cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma","volume":"14","author":"Jiang","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.hoc.2023.12.004_bib78","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/s41467-020-14619-z","article-title":"CD229 CAR T\u00a0cells eliminate multiple myeloma and tumor propagating cells without fratricide","volume":"11","author":"Radhakrishnan","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.hoc.2023.12.004_bib79","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41467-021-27853-w","article-title":"A\u00a0BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers","volume":"13","author":"Wong","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.hoc.2023.12.004_bib80","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/blood-2021-148375","article-title":"Baseline Correlates of Complete Response to Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy in Patients with Relapsed and Refractory Multiple Myeloma: Subanalysis of the KarMMa Trial","volume":"138","author":"Shah","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.004_bib81","doi-asserted-by":"crossref","first-page":"8021","DOI":"10.1200\/JCO.2022.40.16_suppl.8021","article-title":"Correlative analysis to define patient profiles associated with manufacturing and clinical endpoints in relapsed\/refractory multiple myeloma (RRMM) patients treated with idecabtagene vicleucel (ide-cel; bb2121), an anti-BCMA CAR T\u00a0cell therapy","volume":"40","author":"Rytlewski","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2023.12.004_bib82","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1158\/2643-3230.BCD-22-0018","article-title":"Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma","volume":"3","author":"Dhodapkar","year":"2022","journal-title":"Blood cancer Discov"},{"key":"10.1016\/j.hoc.2023.12.004_bib83","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T\u00a0cell landscape determines the response to bispecific T\u00a0cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.hoc.2023.12.004_bib84","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/bloodadvances.2019000600","article-title":"T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma","volume":"3","author":"Garfall","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.hoc.2023.12.004_bib85","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T\u00a0cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.hoc.2023.12.004_bib86","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","article-title":"Homozygous BCMA gene deletion in response to anti-BCMA CAR T\u00a0cells in a patient with multiple myeloma","volume":"27","author":"Da Vi\u00e0","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.hoc.2023.12.004_bib87","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S1470-2045(23)00246-2","article-title":"\u03b3-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial","volume":"24","author":"Cowan","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2023.12.004_bib88","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","article-title":"Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple Myeloma","volume":"1","author":"Fern\u00e1ndez de Larrea","year":"2020","journal-title":"Blood cancer Discov"},{"key":"10.1016\/j.hoc.2023.12.004_bib89","doi-asserted-by":"crossref","first-page":"e19540","DOI":"10.1200\/JCO.2023.41.16_suppl.e19540","article-title":"Outcomes with bendamustine lymphodepletion prior to brexucabtagene autoleucel for mantle cell lymphoma","volume":"41","author":"Chong","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2023.12.004_bib90","doi-asserted-by":"crossref","first-page":"eabg6986","DOI":"10.1126\/scitranslmed.abg6986","article-title":"A\u00a0human orthogonal IL-2 and IL-2R\u03b2 system enhances CAR T\u00a0cell expansion and antitumor activity in a murine model of leukemia","volume":"13","author":"Zhang","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.hoc.2023.12.004_bib91","doi-asserted-by":"crossref","first-page":"295","DOI":"10.18609\/cgti.2018.030","article-title":"Ethical Considerations in the Translation of CAR-T Cell Therapies","volume":"4","author":"Imbach","year":"2018","journal-title":"Cell Gene Ther Insights"},{"key":"10.1016\/j.hoc.2023.12.004_bib92","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2023.11846","article-title":"Fair Allocation of Scarce CAR T-Cell Therapies for Relapsed\/Refractory Multiple Myeloma","author":"Derman","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.hoc.2023.12.004_bib93","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/bloodadvances.2017011254","article-title":"Improving T-cell expansion and function for adoptive T-cell therapy using ex\u00a0vivo treatment with PI3K\u03b4 inhibitors and VIP antagonists","volume":"2","author":"Petersen","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.hoc.2023.12.004_bib94","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","article-title":"A\u00a0combination of humanised anti-CD19 and anti-BCMA CAR T\u00a0cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial","volume":"6","author":"Yan","year":"2019","journal-title":"Lancet Haematol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858823001715?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858823001715?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T05:19:41Z","timestamp":1760591981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858823001715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":94,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0889858823001715"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2023.12.004","relation":{},"ISSN":["0889-8588"],"issn-type":[{"type":"print","value":"0889-8588"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chimeric Antigen Receptor T Cells in the Treatment of Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2023.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}